Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.

In this study, responses to combination immunotherapy were lower than reported. Patients treated with prior immunotherapy had similar responses as treatment-naïve pts. The toxicity profile seen in this study is similar to those reported in clinical trials.